Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Novo Nordisk A/SNYSE: NVO

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin narrows to 34.5%

Operating margin was 34.5% in Q2 FY2026, down 9.0 pp from a year earlier. On a trailing-twelve-month basis it was 43.1%, down 2.6 pp year over year. Over 3 fiscal years it narrowed by 1.0 pp.

Context

  • Operating margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 16 analysts of 42.0% for the fiscal year ending Dec 2026, up from 41.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
34.5%-27.1 pp QoQ
Last fiscal yearDec 2025
41.3%-2.9 pp YoY
LTMJun 2026
43.1%-2.6 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-9.0 pp+6.5 pp+15.5 pp
1 year-2.9 pp+0.7 pp+3.6 pp
3 years-1.0 pp+0.1 pp+1.1 pp
5 years+2.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
41.3%
Year-over-year change
-2.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How NVO compares with its peers on the latest reported figures

  • NVO's LTM Jun 2026 operating margin of 43.1% is the 2nd highest of the 10 companies compared; the peer median is 25.7%.
  • Its year-over-year change of -2.6 pp is the 8th highest of 10, against a peer median of +1.6 pp.
  • Over three fiscal years its change of -1.0 pp compares with a peer median of +1.6 pp.
NVO Competitors Peer median
Operating Margin for NVO and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202649.7% +7.6 pp+15.2 pp
NVONovo Nordisk A/SLTM Jun 202643.1% -2.6 pp-1.0 pp
ABBVAbbVie Inc.LTM Sep 202635.5% +20.4 pp+1.6 pp
AMGNAmgen Inc.LTM Jun 202633.2% +9.7 pp-7.3 pp
PFEPfizer Inc.LTM Jun 202626.7% +0.6 pp-9.9 pp
JNJJohnson & JohnsonLTM Sep 202625.7% -0.4 pp+0.9 pp
AZNAstraZeneca PLCLTM Sep 202623.7% +1.6 pp+14.9 pp
GSKGSK plcLTM Jun 202620.7% +4.5 pp+3.6 pp
MRKMerck & Co., Inc.LTM Jun 202616.7% -16.9 pp+5.3 pp
SNYSanofiLTM Jun 202614.8% -3.6 pp-4.5 pp
Peer median (excluding NVO) 25.7%+1.6 pp+1.6 pp

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue140.8B176.95B232.26B290.4B309.06B
Cost of Revenue23.66B28.45B35.77B44.52B58.79B
Gross Profit117.14B148.51B196.5B245.88B250.28B
Gross Margin83.2%83.9%84.6%84.7%81.0%
Research & Development17.77B24.05B32.44B48.06B52.04B
Selling, General & Admin41.06B50.68B61.6B67.38B70.28B
Operating Expenses58.5B73.7B93.92B117.54B122.62B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
EBITDA65.39B76.8B114.63B147.94B156.73B
EBITDA Margin46.4%43.4%49.4%50.9%50.7%
Operating Income58.64B74.81B102.57B128.34B127.66B
Operating Margin41.7%42.3%44.2%44.2%41.3%
Interest Income231M239M1.07B1.84B1.27B
Interest Expense289M378M542M1.64B4.21B
Other Income / Expenses436M(5.75B)2.1B(1.15B)2.88B
Income Before Tax59.08B69.06B104.67B127.19B130.54B
Pre-Tax Margin42.0%39.0%45.1%43.8%42.2%
Income Tax Expense11.32B13.54B20.99B26.2B28.11B
Net Income47.76B55.53B83.68B100.99B102.43B
Net Margin33.9%31.4%36.0%34.8%33.1%
EPS (Basic)10.4012.2618.6722.6723.06
EPS (Diluted)10.3712.2218.6222.6323.03
Weighted Avg Shares4.59B4.53B4.48B4.45B4.45B
Weighted Avg Shares (Diluted)4.61B4.54B4.49B4.46B4.45B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.